A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment 111In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. 111In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.
From the Departments of *Nuclear Medicine, †Radiology, ‡Ear Nose and Throat, and §Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Received for publication April 3, 2013; revision accepted November 11, 2013.
Conflicts of interest and sources of funding: none declared.
Reprints: Michelle W.J. Versleijen, MD, MSc, PhD, Radboud University Medical Centre, Nijmegen, Department of Nuclear Medicine, Route 757, Geert Grooteplein 10, 6525 GA Nijmegen, the Netherlands. E-mail: firstname.lastname@example.org.